Dinutuximab Beta

Summary

Dinutuximab Beta (CHEMBL5315068) is an approved antibody; indicated across 2 conditions including neuroblastoma and osteosarcoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315068
Name	Dinutuximab Beta
Type	Antibody
Max phase	4

Also known as: Dinutuximab beta, DINUTUXIMAB BETA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neuroblastoma	4	MONDO:0005072	EFO:0000621
osteosarcoma	2	MONDO:0009807	EFO:0000637

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	3
PHASE1	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04221035	PHASE3	RECRUITING	High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT06669013	PHASE3	RECRUITING	Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas
NCT07375563	PHASE3	RECRUITING	Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
NCT05754684	PHASE2	RECRUITING	Quadruple Immunotherapy for Neuroblastoma
NCT07334301	PHASE1/PHASE2	RECRUITING	A Multi-Arm, Platform Trial For Relapsed Neuroblastoma
NCT02308527	PHASE2	COMPLETED	Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
NCT02743429	PHASE2	UNKNOWN	Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma
NCT05080790	PHASE2	COMPLETED	Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
NCT05558280	PHASE2	SUSPENDED	Qarziba for Patients in Relapsed/Refractory High-grade Osteosarcoma
NCT06485947	PHASE1	RECRUITING	Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma
NCT06839703	PHASE1	NOT_YET_RECRUITING	International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma
NCT05373901	PHASE1	COMPLETED	Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participants With High-Risk Neuroblastoma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).